ライフサイエンスコーパス: cardiac surgery

1 th native valve MR who were at high risk for cardiac surgery.

2 r rate of survival among patients undergoing cardiac surgery.

3 sociated with mortality in the 30 days after cardiac surgery.

4 ildren undergoing cardiopulmonary bypass for cardiac surgery.

5 d in younger patients undergoing non-complex cardiac surgery.

6 nded to reduce pulmonary complications after cardiac surgery.

7 similar at centers with and without on-site cardiac surgery.

8 acute myocardial infarction and after major cardiac surgery.

9 n of statin therapy to prevent AKI following cardiac surgery.

10 functional decline after minimally invasive cardiac surgery.

11 actors for retinal artery occlusion (RAO) in cardiac surgery.

12 ranting long-term follow-up after congenital cardiac surgery.

13 ective cohort study of 968 adults undergoing cardiac surgery.

14 mplications in high-risk patients undergoing cardiac surgery.

15 ertension are common 5 years after pediatric cardiac surgery.

16 0.3 mg/dL or more during hospitalization for cardiac surgery.

17 ntion during non-atrial fibrillation-related cardiac surgery.

18 s with critical CHD even before they undergo cardiac surgery.

19 little effect on benchmarking results of all cardiac surgery.

20 rial was performed at 15 European centers of cardiac surgery.

21 l fibrillation is a frequent complication in cardiac surgery.

22 sk is a critical step in decision making for cardiac surgery.

23 t transfusions, and major bleeding following cardiac surgery.

24 ce of delirium in elderly patients after non-cardiac surgery.

25 tional normalised ratio (INR) undergoing non-cardiac surgery.

26 tients undergoing complex procedures such as cardiac surgery.

27 rdial damage in patients undergoing elective cardiac surgery.

28 om patients with heart failure who underwent cardiac surgery.

29 posable income and long-term mortality after cardiac surgery.

30 decisions or guidelines for patients having cardiac surgery.

31 : 314,114 underwent NCS and 12,375 underwent cardiac surgery.

32 91; 49%) with PFE removal at time of another cardiac surgery.

33 The NIS was searched for cardiac surgery.

34 nt is an important determinant of outcome in cardiac surgery.

35 n with a coexisting condition also requiring cardiac surgery.

36 readmission penalties if expanded to include cardiac surgery.

37 evention and the treatment of delirium after cardiac surgery.

38 n and prevention of many complications after cardiac surgery.

39 ypes of HAIs during the first 2 months after cardiac surgery.

40 rgeon an additional technique for performing cardiac surgery.

41 mes criteria within the first 72 hours after cardiac surgery.

42 t benefit among patients undergoing elective cardiac surgery.

43 jury at multiple time points associated with cardiac surgery.

44 ney injury molecule 1 in children undergoing cardiac surgery.

45 severe complication of critical illness and cardiac surgery.

46 mortality, especially in patients with prior cardiac surgery.

47 7; p=0.16) for trials in settings other than cardiac surgery.

48 ification for serious adverse outcomes after cardiac surgery.

49 with AKI and mortality in adults undergoing cardiac surgery.

50 of age or older who were undergoing complex cardiac surgery.

51 end-stage renal disease who were undergoing cardiac surgery.

52 noma or endocrine surgery to 37.0% following cardiac surgery.

53 nitroso-redox balance in patients undergoing cardiac surgery.

54 isk of acute kidney injury in the setting of cardiac surgery.

55 sed to inform transfusion decisions in adult cardiac surgery.

56 ng to septic air emboli and requiring urgent cardiac surgery.

57 0% having functional MR and 60% having prior cardiac surgery.

58 reased morbidity and health care costs after cardiac surgery.

59 s for management of postoperative pain after cardiac surgery.

60 comes analysis for congenital and paediatric cardiac surgery.

61 predictive of infections within 65 days from cardiac surgery.

62 reducing the time to recovery from AKI after cardiac surgery.

63 s in critically ill adults or children after cardiac surgery.

64 enty-four sequential patients admitted after cardiac surgery.

65 of developing dementia within 5 years after cardiac surgery.

66 nated heater-cooler units (HCUs) used during cardiac surgery.

67 (CV) events and mortality in patients after cardiac surgery.

68 Twenty-three percent of patients underwent cardiac surgery.

69 nist, in patients at high risk for AKI after cardiac surgery.

70 treat the low cardiac output syndrome after cardiac surgery.

71 development of dementia within 5 years after cardiac surgery.

72 e perioperative outcome in adults undergoing cardiac surgery.

73 with congenital heart disease, and 54% after cardiac surgery.

74 itioning (RIPC) in patients undergoing adult cardiac surgery.

75 ny patients at extreme risk for conventional cardiac surgery.

76 discharge was less prevalent after PCI than cardiac surgery.

77 %) were conducted at centers without on-site cardiac surgery.

78 morbidity/mortality for children undergoing cardiac surgery.

79 pheral vascular disease and history of prior cardiac surgeries.

80 urgery compared with centers without on-site cardiac surgery (1.4% vs 1.9%; unadjusted odds ratio [OR

81 %, P<0.001) and had higher rates of previous cardiac surgery (18% versus 12%, P<0.001), chronic obstr

82 nce the Fontan procedure included additional cardiac surgery (32%), catheter intervention (62%), arrh

83 s (11.1 versus 11.4 g/dL; P=0.005), previous cardiac surgery (47.8% versus 39.8%; P=0.004), history o

84 tive hemodynamic support was indicated after cardiac surgery, according to prespecified criteria.

85 In these patients with AKI after cardiac surgery, administration of allogeneic MSCs did n

86 ith intraoperative bleeding during high-risk cardiac surgery, administration of fibrinogen concentrat

87 24.3% (65), with 3.4% patients required open cardiac surgery after procedure.

88 ality are lower in obese patients undergoing cardiac surgery, although the nature of this association

89 A total of 9,372 patients underwent 11,968 cardiac surgeries and 1,912 catheter-based interventions

90 e most common noncardiac complications after cardiac surgery and are associated with increased morbid

91 counts for NOS dysfunction in patients after cardiac surgery and cardiopulmonary bypass.

92 All patients undergoing cardiac surgery and congenital interventions in the Unit

93 ion and health-related quality of life after cardiac surgery and ICU admission.

94 MAC also influences the outcomes of cardiac surgery and interventions, and its clinical rele

95 cular dysfunction is a major complication of cardiac surgery and is associated with increased mortali

96 is associated with a poor outcome following cardiac surgery and is generally modified by the use of

97 rging but remain behind adult cardiology and cardiac surgery and leading to partial blindness as to t

98 Cardiac surgery and postoperative admission to the ICU m

99 ars who underwent cardiopulmonary bypass for cardiac surgery and survived hospitalization from 3 Nort

100 (Endo-Group) included patients with previous cardiac surgery and the historical (before May 2013; n=3

101 ill review procedure-specific concerns after cardiac surgery and the management of common complicatio

102 ld improve the management of coagulopathy in cardiac surgery and thereby reduce blood transfusions.

103 es the incidence of AKI in adults undergoing cardiac surgery and this benefit was more pronounced in

104 and adverse outcomes in patients undergoing cardiac surgery and to derive and validate prognosis-bas

105 ss long-term kidney outcomes after pediatric cardiac surgery and to determine if perioperative AKI is

106 icular tissue from human patients undergoing cardiac surgery and used RNA sequencing to describe an l

107 of age or older who were undergoing complex cardiac surgery and were likely to undergo transfusion o

108 ow-up, 4 patients died from complications of cardiac surgery, and 2 patients had their system removed

109 determine the mechanism of chylothorax after cardiac surgery, and analyze the outcomes of lymphatic e

110 arrest, traumatic brain injury, stroke, post-cardiac surgery, and any mechanical ventilation).

111 eimplant tricuspid regurgitation, history of cardiac surgery, and concomitant procedures other than t

112 usion in patients undergoing cardiac and non-cardiac surgery, and observational studies that assessed

113 for patients undergoing orthopedic surgery, cardiac surgery, and those with preexisting cardiovascul

114 year were classified as centers with on-site cardiac surgery, and weighted sampling of all inpatient

115 an angioplasty and stent implantation; 3 had cardiac surgery; and 36 were managed conservatively.

116 notypes are sepsis with acute kidney injury, cardiac surgery, anemia, respiratory failure, heart fail

117 Complications after cardiac surgery are common and lead to substantial incre

118 itically ill children who have not undergone cardiac surgery are lacking.

119 ound protamine-already used clinically after cardiac surgery-as an agent to bind to heparin and there

120 ith heme toxicity as a pathogenic feature of cardiac surgery-associated AKI, and with HO-1 as a poten

121 on registry regarding patients who underwent cardiac surgery at <15 years of age at 1 of 5 universiti

122 ty one consecutive adult patients undergoing cardiac surgery at 3 hospitals in the United States and

123 nical trial of patients with hypoxemia after cardiac surgery at a single ICU in Brazil (December 2011

124 In cardiac surgery, beta-blockers are associated with a low

125 ysis, we included all patients who underwent cardiac surgery between 1999 and 2012 using a large nati

126 genital Heart Surgery Database who underwent cardiac surgery between 2010 and 2011 were included.

127 ents greater than 18 years old who underwent cardiac surgery between January 1, 2006, and April 30, 2

128 arrest (HCA) provides neuroprotection during cardiac surgery but entails an ischemic period that can

129 e risk of bleeding among patients undergoing cardiac surgery, but it is unclear whether this leads to

130 nd reperfusion injury in patients undergoing cardiac surgery, but uncertainty about clinical outcomes

131 nalyze late causes of death after congenital cardiac surgery by era and defect severity.

132 large reductions in costs if HAIs following cardiac surgery can be reduced.

133 tional cardiology, interventional radiology, cardiac surgery, cardiac imaging, and critical care.

134 in the ischemic-preconditioning group) at 30 cardiac surgery centers in the United Kingdom.

135 morbidity and mortality from 80 hospital or cardiac surgery centres in 18 countries undergoing cardi

136 for the main effects revealed that previous cardiac surgery, chromosomal anomaly, and delayed sterna

137 significantly lower at centers with on-site cardiac surgery compared with centers without on-site ca

138 r associate with increased risk of AKI after cardiac surgery, consistent with heme toxicity as a path

139 The armamentarium of cardiac surgery continues to expand, and the cardiac int

140 We obtained data from a nationwide pediatric cardiac surgery database and Finnish population registry

141 ng in the Society of Thoracic Surgeons Adult Cardiac Surgery Database.

142 re obtained retrospectively from a pediatric cardiac surgery database.

143 Successful outcomes after cardiac surgery depend on optimum postoperative critical

144 t dexamethasone-compared with placebo-during cardiac surgery does not positively or negatively affect

145 cutoff to define elderly is controversial in cardiac surgery, empirically ranging from >/=65 to >/=80

146 Prior cardiac surgery, especially the presence of coronary art

147 Twenty AF patients had undergone cardiac surgery exclusively for pulmonary vein isolation

148 Most complications after cardiac surgery fall into a limited number of categories

149 rated health system interventions, including cardiac surgery for congenital and rheumatic heart disea

150 s from children of different ages undergoing cardiac surgery for congenital heart defects were isolat

151 s from children of different ages undergoing cardiac surgery for congenital heart defects were isolat

152 roportion of PCIs at centers without on-site cardiac surgery from 2003 to 2012 in the United States,

153 Data on adult cardiac surgery from 2007 to 2012 (n=95 240) were extrac

154 rial compared methods of fluid removal after cardiac surgery from October 1, 2011, through March 13,

155 matching of male and female participants and cardiac surgery having the worst.

156 Among patients undergoing cardiac surgery, high-dose perioperative atorvastatin tr

157 postoperative pulmonary hypertension who had cardiac surgery; however, it has not been shown to provi

158 Cardiac surgery ICU characteristics and clinician staffi

159 Pennsylvania cardiac surgery ICUs have variable structures, care prac

160 From 2012 to 2013, we conducted a survey of cardiac surgery ICUs in Pennsylvania to assess ICU struc

161 Cardiac surgery ICUs in Pennsylvania.

162 ted from the medical, surgical, cardiac, and cardiac surgery ICUs of a tertiary medical center in the

163 ving patients undergoing elective, high-risk cardiac surgery (ie, combined coronary artery bypass gra

164 of inpatient PCI at centers without on-site cardiac surgery in an unselected and nationally represen

165 he first report on the metabolic response to cardiac surgery in children.

166 ncidence, severity, or duration of AKI after cardiac surgery in high-risk patients.

167 y differences in in-hospital mortality after cardiac surgery in pediatric patients with and without D

168 ation between income and mortality following cardiac surgery in Sweden that was independent of other

169 Early mortality for cardiac surgery in the neonatal period is approximately

170 to reduce the incidence of severe AKI after cardiac surgery in those with advanced CKD.

171 all nonfederal hospitals performing PCI and cardiac surgery in Washington State.

172 Risk factors for RAO in cardiac surgery include giant cell arteritis, carotid st

173 EpiAcc is feasible in patients with previous cardiac surgery, including coronary artery bypass grafts

174 Cardiac surgery, including coronary artery bypass, cardi

175 Complex neonatal cardiac surgery is associated with cerebral injury.

176 Low cardiac output syndrome after cardiac surgery is associated with high morbidity and mo

177 e: Acute kidney injury (AKI) after pediatric cardiac surgery is associated with high short-term morbi

178 Atrial fibrillation after cardiac surgery is associated with increased rates of de

179 AKI after cardiac surgery is associated with mortality, prolonged

180 mine whether the obesity paradox observed in cardiac surgery is attributable to reverse epidemiology,

181 ming of discontinuation of ticagrelor before cardiac surgery is controversial.

182 Cardiac surgery is frequently complicated by coagulopath

183 lts suggest that clinical AKI at the time of cardiac surgery is indicative of concurrent CV stress ra

184 erative death following pediatric congenital cardiac surgery is lacking.

185 iation between income and survival following cardiac surgery is not known.

186 sible for left ventricular dysfunction after cardiac surgery is only partly understood.

187 ntervention (PCI) at centers without on-site cardiac surgery is safe outside of a tightly regulated r

188 by extracorporeal membrane oxygenation after cardiac surgery is uncertain.

189 rative morbidity and health care costs after cardiac surgery is uncertain.

190 More cardiac surgeries, longer hospital stay, poorer linear g

191 ired perioperative hemodynamic support after cardiac surgery, low-dose levosimendan in addition to st

192 However, repeat cardiac surgery may be associated with significant morbi

193 Patients undergoing cardiac surgery may be especially vulnerable to the adve

194 evidence that PCI at centers without on-site cardiac surgery may be safe in the modern era.

195 patients who underwent EpiAcc, 18 had prior cardiac surgery (median age, 64 years, all men).

196 diographic diagnosis, and swift referral for cardiac surgery might impact outcome dramatically.

197 In elective cardiac surgery, MR-pro-adrenomedullin measured between

198 gionella), and heater-cooler devices used in cardiac surgery (Mycobacterium chimaera).

199 tients (n=12) and non-HF subjects undergoing cardiac surgery (n=12) treated with beta-AR blockers rev

200 increasing numbers of elderly people undergo cardiac surgery, neurologists are frequently called upon

201 From 116 patients who underwent elective cardiac surgery on cardiopulmonary bypass, paired sample

202 nary intervention and in patients undergoing cardiac surgery on P2Y12 RI while bleeding with a less e

203 re updated with 1 or 3 years of data, in all cardiac surgery or within operation subgroups.

204 ity between centers with and without on-site cardiac surgery (OR, 1.01; 95% CI, 0.98-1.03; P = .62) f

205 al appendage (LAA) is often performed during cardiac surgery ostensibly to reduce the risk of stroke.

206 tive atrial fibrillation after noncardiac vs cardiac surgery (P < .001 for interaction).

207 were linked to an administrative database of cardiac surgery patient discharges.

208 In 35 cardiac surgery patients (26 with AF), atrial cell telom

209 Among 4,320 cardiac surgery patients (mean age: 64 +/- 13 years), 11

210 ntrolled, randomized clinical trial of adult cardiac surgery patients conducted from November 2009 to

211 e analyzed the survival of all the pediatric cardiac surgery patients operated on before 2010.

212 convey a morbidity and mortality benefit in cardiac surgery patients that persists for 12 months.

213 e race and poor outcomes in small subsets of cardiac surgery patients who require extracorporeal life

214 sma fibrinogen level of 2.5 g/L in high-risk cardiac surgery patients with intraoperative bleeding re

215 (December 2014-June 2015) cases occurred in cardiac surgery patients with invasive infections.

216 Among cardiac surgery patients, combination prophylaxis was as

217 Among MRSA-negative and -unknown cardiac surgery patients, SSIs occurred in 58/6,607 (0.9

218 In cardiac surgery patients, the difference in risk-benefit

219 both early and late results among pediatric cardiac surgery patients.

220 ) of PCI patients and 91% (21 831/23 972) of cardiac surgery patients.

221 ce in the surgical setting comes mainly from cardiac-surgery patients and no predictive-model of post

222 In a large cardiac surgery practice, we built a standardized practi

223 dmitted to the intensive care unit after non-cardiac surgery, prophylactic low-dose dexmedetomidine s

224 detailed analysis of a national, voluntary, cardiac surgery public reporting program using STS clini

225 .94; 95% confidence interval, 4.10-9.49) and cardiac surgery (range 54%-100%; median odds ratio, 7.09

226 In-hospital complications and cardiac surgery rates significantly increased across the

227 vidence from randomised controlled trials in cardiac surgery refutes findings from observational stud

228 Data from the National Adult Cardiac Surgery registry for all cardiac surgical proced

229 ents were prospectively added to a dedicated cardiac surgery registry.

230 Cardiac surgery-related patient isolates were all classi

231 We included 24 M chimaera isolates from 21 cardiac surgery-related patients in Switzerland, Germany

232 his subgroup also comprised isolates from 11 cardiac surgery-related patients reported from the USA,

233 AKI after cardiac surgery remains strongly associated with mortali

234 on clinical outcomes in patients undergoing cardiac surgery remains unclear.

235 Among high-risk patients undergoing cardiac surgery, remote ischemic preconditioning compare

236 New York's Cardiac Surgery Reporting System was used to propensity

237 rs of age who were scheduled for nonemergent cardiac surgery requiring cardiopulmonary bypass and had

238 lving adults who were scheduled for elective cardiac surgery requiring cardiopulmonary bypass under t

239 operative AKI and other adverse events after cardiac surgery requiring cardiopulmonary bypass.

240 adults after gastrointestinal, vascular, or cardiac surgery requiring PN and SICU care.

241 , SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score of >/=11 (the sample median; HR,

242 taneous Coronary Intervention With Taxus and Cardiac Surgery) score quantifies the extent of coronary

243 n SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score was 19.7 +/- 9.6.

244 , SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) score, treatment of saphenous vein graf

245 taneous Coronary Intervention With Taxus and Cardiac Surgery) scores and lesion characteristics were

246 We analyzed PCI and cardiac surgery separately by performing multivariable h

247 Post-cardiac surgery shock is associated with high morbidity

248 For patients with post-cardiac surgery shock requiring high-dose catecholamines

249 Observational studies and trials in non-cardiac surgery should not be used to inform treatment d

250 By contrast, observational cohort studies in cardiac surgery showed that red blood cell transfusion c

251 The Steroids In caRdiac Surgery (SIRS) study is a double-blind, randomis

252 In MRSA-colonized patients undergoing cardiac surgery, SSI occurred in 8/346 (2.3%) patients w

253 ermediate Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score (random-effects: HR, 1.02

254 taneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score of 32 or lower (the SYNTA

255 ed by the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score.

256 taneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial is a multicenter, randomi

257 taneous Coronary Intervention With Taxus and Cardiac Surgery [SYNTAX]; NCT00114972).

258 mong the cohort of 15171 patients undergoing cardiac surgery, the median age was 71 years and 4622 we

259 Among patients with hypoxemia after cardiac surgery, the use of an intensive vs a moderate a

260 sinus rhythm who were scheduled for elective cardiac surgery to receive perioperative rosuvastatin (a

261 had echocardiographic evidence of PFE but no cardiac surgery to remove PFE.

262 ores indicating a higher risk of death after cardiac surgery) to a restrictive red-cell transfusion t

263 ycemia (excluding patients who had undergone cardiac surgery) to one of two ranges of glycemic contro

264 Advances in cardiac surgery toward the mid-20th century created a ne

265 (Frailty Assessment Before Cardiac Surgery & Transcatheter Interventions; NCT018452

266 taneous Coronary Intervention With Taxus and Cardiac Surgery) trial, patients with 3-vessel or left m

267 an 60 years undergoing major cardiac and non-cardiac surgery under general anaesthesia.

268 ative atrial fibrillation who are undergoing cardiac surgery undergo concomitant atrial fibrillation

269 xplained only 10% of PCI variation and 0% of cardiac surgery variation.

270 A restrictive transfusion threshold after cardiac surgery was not superior to a liberal threshold

271 allocation bias, LAA closure during routine cardiac surgery was significantly associated with an inc

272 Cardiac surgery was the gold standard.

273 pensity adjustment for likelihood to receive cardiac surgery was used to evaluate the impact of EVS a

274 amethasone in 4465 adult patients undergoing cardiac surgery, we examined severe AKI, defined as use

275 ears of age who were undergoing nonemergency cardiac surgery were recruited from 17 centers in the Un

276 of brain injury is increased during neonatal cardiac surgery, where pre-existing hemodynamic instabil

277 llation (POAF) is a frequent complication of cardiac surgery, which results in increased morbidity, m

278 or excessive bleeding in patients undergoing cardiac surgery while on a maintenance dose of aspirin a

279 we randomly assigned 5243 adults undergoing cardiac surgery who had a European System for Cardiac Op

280 In patients undergoing cardiac surgery who were at moderate-to-high risk for de

281 ing high-dose catecholamines 3-24 hours post-cardiac surgery who were randomized to early HVHF (80 ml

282 algorithm in consecutive patients undergoing cardiac surgery with cardiopulmonary bypass at 12 hospit

283 ive AKI in 2377 white patients who underwent cardiac surgery with cardiopulmonary bypass.

284 atients who are nonthrombocytopenic and have cardiac surgery with cardiopulmonary bypass.

285 effect on mortality or major morbidity after cardiac surgery with cardiopulmonary bypass.

286 eligible infants (aged <6 months) undergoing cardiac surgery with catheter placement for PD were appr

287 ing cell-free (cf)DNA in patients undergoing cardiac surgery with CPB.

288 ients admitted to intensive care units after cardiac surgery with early acute kidney injury (>/=50% i

289 We randomized 156 adult subjects undergoing cardiac surgery with evidence of early AKI to receive in

290 tive sample of adult patients undergoing non-cardiac surgery with preoperative INR greater than or eq

291 c surgery centres in 18 countries undergoing cardiac surgery with the use of cardiopulmonary bypass t

292 fraction of 35% or less who were undergoing cardiac surgery with the use of cardiopulmonary bypass.

293 icular ejection fraction who were undergoing cardiac surgery with the use of cardiopulmonary bypass.

294 Obesity is associated with lower risks after cardiac surgery, with consistent effects noted in multip

295 ependent predictor of adverse outcomes after cardiac surgery, with each 0.1-m/s decrease conferring a

296 e admitted to intensive care units after non-cardiac surgery, with informed consent.

297 orporeal membrane oxygenation patients after cardiac surgery, with persistent severe thrombocytopenia

298 Infants with single ventricle require staged cardiac surgery, with stage I typically performed shortl

299 roportion of PCIs at centers without on-site cardiac surgery within the study period (from 1.8% to 12

300 mber needed to harm for severe AKI following cardiac surgery would be 167.